Europe Sepsis Diagnostics Market

Europe Sepsis Diagnostics Market Size (2022 to 2027)

The size of the sepsis diagnostics market in Europe was valued at USD 430.63 Million in 2022 and is estimated to be worth USD 645.43 Million by 2027, growing at a CAGR of 8.43% during the forecast period.

Sepsis Diagnosis is on the rise as the incidence rate, and prevalence of sepsis are on the rise. Sepsis is a severe illness condition occurring when the body reacts to a bacterial, viral, fungal, or parasitic foreign body infection. It is one of the most death-causing diseases in hospitals. The contamination leads to organ dysfunction or failure and systemic inflammation. Its symptoms are hypertension, high body temperature, shivering, and elevated heart rate. The increasing prevalence of the disease and its fatal effects have stimulated its growth.

An increase in sepsis incidences with the growing regulatory approval and the development of technologically improved diagnostic solutions are likely to be the major drivers accelerating the growth rate of the European sepsis diagnostics market expansion. In addition, the increase in financing for sepsis-related research activities, an increase in the number of sepsis procedures, with the rise in the prevalence of antibiotic-resistant bacterial strains are expected to propel the market growth.

On the other hand, an increase in the incidence of diagnostic solutions, spreading awareness with the help of government initiatives, an increase in the number of pneumonia cases, and market key players are other factors driving the market growth.

The key factors obstructing the sepsis diagnostics market growth in the European region are the lack of standard protocols for treating sepsis in some countries and the lack of awareness about the complications of sepsis diagnostics. Also, a shortage of skilled professionals in the healthcare industry has always been a significant challenge among the countries. Furthermore, sepsis diagnostics also cost a considerable amount, and it also restricts the market’s growth.

Impact of COVID-19 on the European sepsis diagnostics market:

The covid 19 pandemics have proven to the havoc on the healthcare industry, and sepsis diagnostics is no excuse. The covid 19 pandemics have increased the competition for hospital beds, and people getting admitted to hospitals have increased. In turn, the chances of encountering sepsis due to hospital have also increased. Therefore, the need for sepsis diagnostics has been increasing and is expected to increase further in the near future. The supply chain, however, is adversely affected and expected to improve after the restrictions are removed.

This research report has been segmented and sub-segmented the European Sepsis Diagnostics Market into the following categories:

By Pathogen:

• Bacterial Sepsis    
  • Gram-Negative Bacterial Sepsis
  • Gram-Positive Bacterial Sepsis
• Fungal Sepsis        
• Other Pathogen Infections

By Product:

• Instruments          
• Blood Culture Media          
• Assay Kits & Reagents       
• Software  

By Technology:

• Microbiology         
• Molecular Diagnostics       
• Immunoassays    
• Flow Cytometry  
• Other Technologies

By Method:

• Conventional Diagnostics
• Automated Diagnostics

By Usability:

• Laboratory Testing              
• Point-of-Care Testing

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the European sepsis diagnostics market accounted for a substantial share in the global market in 2020. Among various nations of Europe, the German sepsis diagnostics market is forecasted to grow at a promising CAGR and play a leading role. In Germany, sepsis is a prevalent and often deadly disease in pediatric patients, especially in newborns and children suffering from more than one illness at the same time.

The UK sepsis diagnostics market is estimated to register a healthy CAGR during the forecast period. However, according to a new study in the UK, sepsis kills more people than breast and pancreatic cancer. It is because of the staff shortage and overcrowding of the hospitals which led to an increase in the sepsis death rate, and according to the Sepsis Trust, there are around 245,783 cases in the UK each year in that half of the people including die because of sepsis and mostly suffer permanently.

KEY MARKET PLAYERS:

Some of the leading companies operating in the European Sepsis Diagnostics market profiled in the report are bioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.